OncLive TV

Carlo Visco, MD, highlights the clinical relevance of reducing the dose of certain RBAC components when administering this regimen in high-risk MCL.

R. Lor Randall, MD, FACS, discusses a new STS surveillance algorithm based on findings that show the comparable diagnostic utility of ultrasound and MRI.

Amit Mehta, MD, outlines the common toxicities encountered with immunotherapy-containing regimens in urothelial cancer and strategies to mitigate them.

Fred Saad, MD, discusses the importance of timing when incorporating radium-223 into prostate cancer treatment.

Martin Dreyling, MD, speculated on the future role of BTK inhibitors either alone or in non-cytotoxic chemotherapy combinations for patients with MCL.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the design the PSMAddition trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Shilpa Gupta, MD, discusses future research directions for enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Sarah Lynam, MD, discusses the clinical applicability of mirvetuximab soravtansine and trastuzumab deruxtecan in recurrent ovarian cancer.

Tarek Mouhieddine, MD, discusses future research directions with ferritin and ALC as biomarkers of response to bispecific antibodies in myeloma.

Percy Lee, MD, discussed the use of SABR within the larger radiation therapy paradigm for the management of non–small cell lung cancer.

Akriti G. Jain, MD, detailed the current unmet needs in polycythemia vera and myelofibrosis, including how to define disease modification.

Randy F. Sweis, MD, discusses shares how XmAb819 may address the need for effective therapies after progression on standard regimens in RCC.

Solange Peters, MD, PhD, discusses findings for obrixtamig plus atezolizumab/chemotherapy in first-line extensive-stage small cell lung cancer.

Lu Xie, MD, discusses the scientific rationale and clinical development strategy for HS-20093 in the phase 2 ARTEMIS-002 trial.

Vanda Salutari, MD, discusses the rationale for examining relacorilant plus nab-paclitaxel in PARP inhibitor–treated platinum-resistant ovarian cancer.

Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive, HER2-positive metastatic disease.

Pule Wang, MD, discusses the design of a retrospective study of CNS bridging radiation therapy prior to CAR T in B-cell lymphomas.

Paolo Tarantino, MD, PhD, discusses key efficacy data with de-escalated THP with/without carboplatin in HER2-positive breast cancer.

Carlo Visco, MD, discussed patient characteristics, efficacy data, and safety findings from the FIL_V-RBAC study of venetoclax plus RBAC in MCL.

R. Lor Randall, MD, FACS, summarizes the current status of and future directions for imaging protocols for post-surgical extremity STS surveillance.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the background of a phase 3 trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Jessica C. Hassel, MD, discusses rationale for combining IO102-IO103 with pembrolizumab in patients with treatment-naive advanced melanoma.

Martin Dreyling, MD, provides recommendations for use of acalabrutinib plus BR in pretreated MCL based on updated data from the phase 3 ECHO trial.

Shilpa Gupta, MD, discusses response and subgroup data with enfortumab vedotin plus pembrolizumab in locally advanced/ metastatic urothelial carcinoma.

Sarah Lynam, MD, details key efficacy data from the phase 2 DESTINY-PanTumor02 trial, evaluating trastuzumab deruxtecan in HER2-expressing solid tumors.

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.

Tarek Mouhieddine, MD, discusses data from a study of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory myeloma.

Percy Lee, MD, discusses different radiation modalities for patients with NSCLC, the increasing complexity of reirradiation, and the strategic use of SABR.

Xiuning Le, MD, PhD, discusses findings from the phase 1/2 SOHO-01 trial evaluating sevabertinib monotherapy in HER2-mutant advanced NSCLC.